Trials / Completed
CompletedNCT03370133
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 567 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Bimekizumab will be provided at pre-specified time intervals. |
| DRUG | Ustekinumab | Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals. |
| OTHER | Placebo | Subjects will receive Placebo at pre-specified time points. |
Timeline
- Start date
- 2017-12-06
- Primary completion
- 2019-01-08
- Completion
- 2019-12-13
- First posted
- 2017-12-12
- Last updated
- 2026-04-15
- Results posted
- 2022-02-03
Locations
105 sites across 11 countries: United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03370133. Inclusion in this directory is not an endorsement.